By Fineline Cube 
Genhouse Bio, a small‑molecule oncology company incubated by Viva Biotech, announced the completion of a cross‑over financing round exceeding RMB 300 million led by Green Pine Capital Partners (GPCP), with participation from Linzhuo Investment, Yuanbio Venture Capital, Guangzhou Industrial Investment, VIVATEC, BOHE Angel Fund, and Guoju Investment.
Financing Structure
| Item | Detail |
|---|---|
| Company | Genhouse Bio (Viva Biotech incubator) |
| Round Type | Cross‑over (Pre‑IPO) |
| Total Raised | RMB 300 million+ (≈ USD 41.5 million) |
| Lead Investor | Green Pine Capital Partners (GPCP) |
| Co‑Investors | Linzhuo Investment, Yuanbio Venture Capital, Guangzhou Industrial Investment, VIVATEC, BOHE Angel Fund, Guoju Investment |
| Use of Proceeds | Advance pipeline from discovery to clinical development, scale AI platform |
| Valuation | Undisclosed; cross‑over round implies pre‑IPO positioning |
Company Profile & Technology
- Focus: Development of world‑leading small‑molecule targeted anti‑tumor drugs
- R&D Philosophy: “AI/Biology‑Driven Smart Design” – deep integration of computational chemistry, artificial intelligence, and internal experimental platforms
- Operational Model: “Data‑driven, rapid iteration” – high‑efficiency system spanning drug discovery to clinical development
- Pipeline: Undisclosed number of programs; all assets leverage AI‑enabled de‑novo design and multi‑parameter optimization
- Differentiation: Full‑stack AI integration (design → synthesis → testing → clinical) vs. traditional CRO‑dependent models
Market Context & Strategic Positioning
| Parameter | 2026E | 2027E | 2028E |
|---|---|---|---|
| China AI Drug Discovery Market | ¥4.5 billion | ¥6.2 billion | ¥8.5 billion |
| Small‑Molecule Oncology Share | 55 % | 52 % | 50 % |
| Genhouse Pipeline Value (est.) | ¥800 million | ¥1.5 billion | ¥3.2 billion |
| IPO Timeline | – | H2 2027 (target) | – |
- Competitive Landscape:
- Insilico Medicine (HK), Genesis Biotech dominate AI‑driven discovery; Genhouse differentiates via full pipeline ownership and biology‑driven platform
- Schrödinger (US) focuses on software licensing; Genhouse operates asset‑centric model
- Investor Strategic Value:
- Green Pine Capital gains exposure to pre‑IPO AI biotech with cross‑over risk‑return profile
- Guangzhou Industrial Investment signals regional government support for AI‑enabled drug development
- VIVATEC (Viva Biotech’s fund) provides strategic synergy with Viva’s CRO platform
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Genhouse Bio’s pipeline advancement, IPO timeline, and market positioning. Actual results may differ due to clinical trial outcomes, competitive dynamics in AI drug discovery, and capital market conditions.-Fineline Info & Tech